

Patient Name: PIROG, BEATA

MRN: 3835899

DOB: 7/9/1966 Age: 57 years Sex: Female

Bellevue Hospital Center Department of Pathology

462 First Avenue

New York, NY 10016

Tel:(212) 562-3411 Fax: (212) 263-8284

CLIA#: 33D0653357

Location: BE ONCOLOGY CC

Ordering Provider: SILK,TARIK

Surgical Pathology Report

ACCESSION #: 31-HP-24-000973

COLLECTED DATE/TIME: 2/1/2024 15:56 EST

RECEIVED DATE/TIME: 2/1/2024 17:34 EST

Surgical Pathology Report – Auth (Verified)**Diagnosis**

Procedure	Event Code	Result	Reference Range
<i>Clinical Date: 01/30/24 15:05 EST</i>			
CBC/Diff	WBC	9.29 x10(3)/mcL	4.80 - 10.80
<i>Clinical Date: 01/30/24 15:05 EST</i>			
CBC/Diff	RBC	4.22 x10(6)/mcL	4.20 - 5.40
<i>Clinical Date: 01/30/24 15:05 EST</i>			
CBC/Diff	HGB	12.3 g/dL	12.0 - 16.0
<i>Clinical Date: 01/30/24 15:05 EST</i>			
CBC/Diff	HCT	37.3 %	37.0 - 47.0
<i>Clinical Date: 01/30/24 15:05 EST</i>			
CBC/Diff	MCH	29.1 pg	27.0 - 31.0
<i>Clinical Date: 01/30/24 15:05 EST</i>			
CBC/Diff	MCHC	33.0 g/dL	29.8 - 35.2
<i>Clinical Date: 01/30/24 15:05 EST</i>			
CBC/Diff	MCV	88.4 fL	80.0 - 99.0
<i>Clinical Date: 01/30/24 15:05 EST</i>			
CBC/Diff	MPV	9.7 fL	8.7 - 12.9
<i>Clinical Date: 01/30/24 15:05 EST</i>			
CBC/Diff	PLT	427 x10(3)/mcL	150 - 450

As of: 02/01/24 17:40 EST

SEE ATTACHED REPORT

Verified By:

John D Andersen, DO

(Electronic signature)

Report Date/Time: 02/05/24 14:48 EST

NYC Health + Hospitals / Bellevue

462 First Avenue

New York, NY 10016

Specimen Source

A Bone Marrow core

B Bone Marrow Aspirate clot

C Bone Marrow Aspirate slides

Unless otherwise specified, all tests are performed at:

NYC Health + Hospital / Bellevue Hospital Center Department of Pathology,
462 First Avenue, New York, NY 10016

Patient Name: PIROG, BEATA

Printed: 2/5/2024 14:48 EST

RRID: 10536655

Page 1 of 9

Patient Name: **PIROG, BEATA**

MRN: 3835899

FIN: 211560354

Surgical Pathology Report

ACCESSION #: 31-HP-24-000973

COLLECTED DATE/TIME:
2/1/2024 15:56 EST

RECEIVED DATE/TIME:
2/1/2024 17:34 EST

Specimen Source

D Bone Marrow Aspirate blood

Clinical History

Collection Date (T for Today):->2/1/24

Collection Time (N for Now):-> 3:54 PM

Clinical history:->multiple myeloma

Procedure:->bone marrow biopsy

Number of Specimens->4

Specimen A Frozen?->No

Specimen B Frozen?->No

Specimen C Frozen?->No

Specimen D Frozen?->No

Gross Description

Received with accession number 31-HP-24-000973, patient's name (initials "BP"), medical record number. The specimen consists of a green top tube, (5) five aspirate smears, a bone marrow core and a bone marrow aspirate clot in formalin containers. The specimen is entirely submitted to NYU Hematopathology for processing.

Gross examination and transcription only performed by: Gerald Davydov PA, HTL(ASCP)

Gross Date/Time: 02/01/24 17:40 EST

Disclaimer

"The electronic signature attests that the named Attending Pathologist has evaluated the specimen referred to in the signed section of the report and formulated the diagnosis therein. The date and time of each electronic signature is the date and time the result is reported and available to the provider. This report may include results from one or more molecular tests that were developed and their performance characteristics determined by an outside laboratory, such as Genpath Foundation Medicine, Integrated Oncology, or other. This report may include one or more histochemical, immunohistochemical, in-situ hybridization stain results that use analyte specific reagents (ASR), for which accuracy and precision have been established and verified. These tests were developed and their performance characteristics determined by either the outside laboratory, or the Hospital's Pathology Laboratory. The adequacy of testing is verified by appropriate controls. All controls show appropriate reactivity. Stains and tests have not been validated on tissue processing other than formalin-fixation, such as decalcification, alcohol-based-fixation, or other. These Immunohistochemical and in-situ hybridization tests are not cleared or approved by the US Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. These assays are for clinical use and should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high complexity clinical laboratory testing."

Unless otherwise specified, all tests are performed at:

*NYC Health + Hospital / Bellevue Hospital Center Department of Pathology,
462 First Avenue, New York, NY 10016*

Printed: 2/5/2024 14:48 EST

RRID: 10536655

Patient Name: **PIROG, BEATA**


Page 2 of 9

7/9/1966

* Auth (Verified) *

Fax Server

2/4/2024 11:01:54 AM AEST PAGE 5/006 Fax Server

**NYU Langone Hospitals - 38th Street Molecular Pathology**

240 East 38th Street, 22nd Floor, New York, NY 10016

Phone: 212-263-5967 Fax: 212-263-7712

Pirog, Beata 16097165

F, 57 yrs, 7/9/1966

6051 68th Road, RIDGEWOOD NY 11385

H: 929-309-5517 M: 929-309-5517

Flow Cytometry Report (Final result)

HP24-01173

Authorizing Provider:	Pratibha S Shukla, MD	Ordering Provider:	Pratibha S Shukla, MD
Ordering Location:	TH ACC 38ST PATHOLOGY	Collected:	02/01/2024 1400
Pathologist:	Chimene Kesserwan, MD	Received:	02/02/2024 1004

Specimens

A Bone Marrow Aspirate, 31-HP-24-973

Flow Interpretation

No immunophenotypic evidence for hematolymphoid neoplasm

Note: Analyzed for plasma cell neoplasm MRD at a sensitivity level of 0.01%. Morphologic evaluation will be issued subsequently.

Results of this study should be correlated with the concurrent bone marrow case, BM24-00205

Specimen Source

Bone Marrow Aspirate

Cell Viability and Count

The specimen has a viability of 100%. The number of cells recovered is 3.8x10^6.

Immunophenotyping

Immunophenotypic analysis demonstrates 66% maturing granulocytic elements, 2.8% monocytes, 0.43% CD34(+) myeloblasts, 23% small T lymphocytes (CD4:CD8= 0.45:1), 0.09% NK cells, 0.10% hematogones, 0.11% small mature polytypic B lymphocytes (kappa:lambda= 1.7:1). The remaining events are attributable to uncharacterized cells and debris.

Flow Antibodies Tested

B Cells	
Marker	Value
CD10	:
CD19	:
CD20	:
CD23	:
cKAPPA	:
cLAMBDA	:

Pirog, Beata
MRN: 16097165HP24-01173
Page 1 of 2

7/9/1966

* Auth (Verified) *

Fax Server

2/4/2024 11:01:54 AM AEST PAGE 6/006 Fax Server

NYU Langone Hospitals
38th Street Molecular Pathology
 240 East 38th Street, 22nd Floor, New York, NY 10016 Phone: 212-263-5967
 Fax: 212-263-7712

KAPPA
 LAMBDA

T Cells

Marker	Value
CD2	.
CD3	.
CD4	.
CD5	.
CD7	.
CD8	.

Myeloid Cells

Marker	Value
CD117	.
CD13	.
CD14	.
CD15	.
CD33	.

Miscellaneous

Marker	Value
CD138	.
CD34	.
CD36	.
CD38	.
CD45	.
CD56	.
CD64	.
HLA-DR	.

Disclaimer

The electronic signature attests that the named Attending Pathologist has evaluated the patient material referred to in the signed section of the report and formulated the diagnosis therein. The date and time of each electronic signature is the date and time the result is reported and available to the provider. This report may include results from one or more molecular tests that were developed and their performance characteristics determined NYU Langone Hospitals - 38th Street Molecular Pathology, 240 East 38th St, 22nd Floor, New York, NY 10016. This report may include one or more histochemical, immunohistochemical, and insitu hybridization stain results that use analyte specific reagents. The tests were developed and their performance characteristics determined by NYU Langone Hospitals - Tisch Hospital Pathology, 560 First Ave, New York, NY 10016. These molecular, immunohistochemistry, and insitu hybridization tests are not cleared or approved by the US Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. The adequacy of testing is verified by appropriate controls. These assays are for clinical use and should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high complexity clinical laboratory testing.

Electronically signed by Chimene Kesserwan, MD on 2/4/2024 at 1024

Pirog, Beata
 MRN: 16097165


HP24-01173
 Page 2 of 2

7/9/1966

* Auth (Verified) *

Fax Server

2/5/2024 11:02:29 AM AEST PAGE 7/011 Fax Server

**NYU Langone Hospitals - 38th Street Molecular Pathology**

240 East 38th Street, 22nd Floor, New York, NY 10016

Phone: 212-263-5967 Fax: 212-263-7712

Pirog, Beata 16097165

F, 57 yrs, 7/9/1966

6051 68th Road, RIDGEWOOD NY 11385

H: 929-309-5517 M: 929-309-5517

Bone Marrow Pathology Report (Final result)

BM24-00205

Authorizing Provider:	Pratibha S Shukla, MD	Ordering Provider:	Pratibha S Shukla, MD
Ordering Location:	TH ACC 38ST PATHOLOGY	Collected:	02/01/2024 1400
Pathologist:	Nicholas D Ward, MD	Received:	02/02/2024 1003

Specimens

- A Bone Marrow Core Bx, 31-HP-24-973-A
- B Bone Marrow Smear, 31-HP-24-973-B, 5 SMEARS
- C Bone Marrow Clot, 31-HP-24-973-C

Final Diagnosis

BONE MARROW CLOT SECTION, ASPIRATE AND CORE BIOPSY:

- Hemodilute aspirate smears and core biopsy with only focal hematopoietic elements exhibiting crush artifact see comment)

Comment: Sections show a small core biopsy consisting of paracortical soft-tissue, trabecular bone associated with predominately crushed hematopoietic elements precluding adequate cytologic evaluation. Bone marrow clot sections show red blood cells and fibrin clot with essentially no marrow elements available for interpretation. Aspirate smears are aparticulate and hemodilute showing mature peripheral blood elements. Concurrent flow cytometry reports no immunophenotypic evidence for a hematopoietic/plasma cell neoplasm. The histologic material provided is inadequate for interpretation; rebiopsy should be clinically considered.

Clinical History

MM

Gross Description

A. Received in formalin, labeled with the patient's name (initials: BP) and designated "bone marrow core", is a tan, minimally hemorrhagic, cylindrical and firm bone core measuring 0.5 x 0.2 x 0.2 cm. Adherent to the bone core is a dark red strand of clotted blood measuring 0.9 x 0.2 x 0.1 cm. The specimen is entirely submitted in two cassettes labeled A1-A2 (A1 = bone core after decalcification; A2 = clotted blood).

AL 02/02/2024

Bone Marrow Aspirate Specimen

C. Received in formalin, labeled with the patient's name (initials: BP) and designated "bone marrow aspirate clot", are two fragments of glistening, dark red, rubbery and smooth clotted blood measuring 2.2 x 1.2 x 0.2 cm, overall. The specimen is entirely submitted in one cassette. C1 in toto.

Pirog, Beata
MRN: 16097165

BM24-00205
Page 1 of 5

7/9/1966

* Auth (Verified) *

Fax Server

2/5/2024 11:02:29 AM AEST PAGE 8/011 Fax Server

NYU Langone Hospitals
38th Street Molecular Pathology
240 East 38th Street, 22nd Floor, New York, NY 10016 Phone: 212-263-5967
Fax: 212-263-7712

AL 02/02/2024

Microscopic Description**FLOW CYTOMETRY (HP24-01173):**

Immunophenotypic analysis demonstrates 66% maturing granulocytic elements, 2.8% monocytes, 0.43% CD34(+) myeloblasts, 23% small T lymphocytes (CD4:CD8= 0.45:1), 0.09% NK cells, 0.10% hematogones, 0.11% small mature polytypic B lymphocytes (kappa:lambda= 1.7:1). The remaining events are attributable to uncharacterized cells and debris.

PERIPHERAL BLOOD DATA:

Not provided.

IRON:

Too few particles to accurately assess iron stores on the bone marrow aspirate (performed at the flow cytometry lab), core biopsy and clot sections (A2, C1).

RETICULIN:

Reticulin stain is performed on the core biopsy and clot section (C1), but not enough bone marrow elements provided for adequate assessment.

ASPIRATE SMEAR(s):

Wright-Giemsa stains of the bone marrow aspirate smears are examined and aparticulate and hemodilute showing essentially mature peripheral blood elements.

BONE MARROW BIOPSY:

H&E stains of the bone marrow core biopsy are examined and show a small core biopsy consisting of paracortical soft-tissue, trabecular bone associated with predominately crushed hematopoietic elements precluding adequate cytologic evaluation. Immunohistochemical stains demonstrate plasma cells (CD138+).


7/9/1966

* Auth (Verified) *

Fax Server

2/5/2024 11:02:29 AM AEST PAGE 9/011 Fax Server

NYU Langone Hospitals
38th Street Molecular Pathology
240 East 38th Street, 22nd Floor, New York, NY 10016 Phone: 212-263-5967
Fax: 212-263-7712

**ASPIRATE CLOT:**

H&E stains of the bone marrow clot section are examined and show red blood cells and fibrin clot with essentially no marrow elements available for interpretation; overall non-contributory.

Disclaimer

The electronic signature attests that the named Attending Pathologist has evaluated the patient material referred to in the signed section of the report and formulated the diagnosis therein. The date and time of each electronic signature is the date and time the result is reported and available to the provider. Specimen processing performed at NYU Langone Hospitals - Tisch Hospital Pathology, 560 First Avenue, New York, NY, 10016. 212-263-5470. This report may include results from one or more molecular tests that were developed and their performance characteristics determined by NYU Langone Hospitals - 38th Street Molecular Pathology, 240 East 38th St, 22nd Floor, New York, NY 10016. This report may include one or more histochemical, immunohistochemical, and insitu hybridization stain results that use analyte specific reagents. The tests were developed and their performance characteristics determined by NYU Langone Hospitals - Tisch Hospital Pathology, 560 First Ave, New York, NY 10016. These molecular, immunohistochemistry, and insitu hybridization tests are not cleared or approved by the US Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. The adequacy of testing is verified by appropriate controls. These assays are for clinical use and should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high complexity clinical laboratory testing.

Electronically signed by Nicholas D Ward, MD on 2/5/2024 at 1012

Related Orders

Flow Cytometry Report (Final result)		HP24-01173	
Authorizing Provider:	Pratibha S Shukla, MD	Ordering Provider:	Pratibha S Shukla, MD

Pirog, Beata
MRN: 16097165

BM24-00205
Page 3 of 5

7/9/1966

* Auth (Verified) *

Fax Server

2/5/2024 11:02:29 AM AEST PAGE 10/011 Fax Server

NYU Langone Hospitals
38th Street Molecular Pathology
 240 East 38th Street, 22nd Floor, New York, NY 10016 Phone: 212-263-5967
 Fax: 212-263-7712

Ordering Location:	TH ACC 38ST PATHOLOGY	Collected:	02/01/2024 1400
Pathologist:	Chimene Kesserwan, MD	Received:	02/02/2024 1004

Specimens

A Bone Marrow Aspirate, 31-HP-24-973

Flow Interpretation

No immunophenotypic evidence for hematolymphoid neoplasm

Note: Analyzed for plasma cell neoplasm MRD at a sensitivity level of 0.01%. Morphologic evaluation will be issued subsequently.

Results of this study should be correlated with the concurrent bone marrow case, BM24-00205

Specimen Source

Bone Marrow Aspirate

Cell Viability and Count

The specimen has a viability of 100%. The number of cells recovered is 3.8x10⁶.

Immunophenotyping

Immunophenotypic analysis demonstrates 66% maturing granulocytic elements, 2.8% monocytes, 0.43% CD34(+) myeloblasts, 23% small T lymphocytes (CD4:CD8= 0.45:1), 0.09% NK cells, 0.10% hematogones, 0.11% small mature polytypic B lymphocytes (kappa:lambda≈ 1.7:1). The remaining events are attributable to uncharacterized cells and debris.

Flow Antibodies Tested**B Cells**

Marker	Value
CD10	:
CD19	:
CD20	:
CD23	:
cKAPPA	:
CLAMBDA	:
KAPPA	:
LAMBDA	:

T Cells

Marker	Value
CD2	:
CD3	:
CD4	:
CD5	:
CD7	:
CD8	:

Pirog, Beata
 MRN: 16097165

BM24-00205
 Page 4 of 5

7/9/1966

* Auth (Verified) *

Fax Server

2/5/2024 11:02:29 AM AEST PAGE 11/011 Fax Server

NYU Langone Hospitals
38th Street Molecular Pathology
 240 East 38th Street, 22nd Floor, New York, NY 10016 Phone: 212-263-5967
 Fax: 212-263-7712

Myeloid Cells

Marker	Value
CD117	:
CD13	:
CD14	:
CD15	:
CD33	:

Miscellaneous

Marker	Value
CD138	:
CD34	:
CD36	:
CD38	:
CD45	:
CD56	:
CD64	:
HLA-DR	:

Disclaimer

The electronic signature attests that the named Attending Pathologist has evaluated the patient material referred to in the signed section of the report and formulated the diagnosis therein. The date and time of each electronic signature is the date and time the result is reported and available to the provider. This report may include results from one or more molecular tests that were developed and their performance characteristics determined NYU Langone Hospitals - 38th Street Molecular Pathology, 240 East 38th St, 22nd Floor, New York, NY 10016. This report may include one or more histochemical, immunohistochemical, and insitu hybridization stain results that use analyte specific reagents. The tests were developed and their performance characteristics determined by NYU Langone Hospitals - Tisch Hospital Pathology, 560 First Ave, New York, NY 10016. These molecular, immunohistochemistry, and insitu hybridization tests are not cleared or approved by the US Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. The adequacy of testing is verified by appropriate controls. These assays are for clinical use and should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high complexity clinical laboratory testing.

Electronically signed by Chimene Kesserwan, MD on 2/4/2024 at 1024

Pirog, Beata
 MRN: 16097165

BM24-00205
 Page 5 of 5